GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (NAS:HOLX) » Definitions » Deferred Tax

HOLX (Hologic) Deferred Tax : $-74 Mil (TTM As of Dec. 2024)


View and export this data going back to 1990. Start your Free Trial

What is Hologic Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Hologic's change in deferred tax for the three months ended in Dec. 2024 was $-20 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2024 was $-74 Mil.

Hologic Deferred Tax Historical Data

The historical data trend for Hologic's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hologic Deferred Tax Chart

Hologic Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only -94.40 -70.10 -166.20 -109.10 -72.10

Hologic Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.60 -29.20 -5.50 -19.80 -19.50

Hologic Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-74 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hologic Deferred Tax Related Terms

Thank you for viewing the detailed overview of Hologic's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Hologic Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (NAS:HOLX) » Definitions » Deferred Tax
Comparable Companies
ALGN WST AVTR BAX COO ATR RGEN TFX MMSI STVN ISRG XPAR:EL BDX XSWX:ALC TSE:7741 RMD TSE:4543 OCSE:COLO B XSWX:STMN XPAR:DIM
Traded in Other Exchanges
0J5Q:UK HO1:Germany HOLX:Austria
Address
250 Campus Drive, Marlborough, MA, USA, 01752
Website
https://www.hologic.com
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Executives
Essex D Mitchell officer: Div. President, GYN Surgical 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Karleen Marie Oberton officer: Corp. VP, Finance & Acconting 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Benjamin Jordan Cohn officer: Principal Accounting Officer 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Stephen P Macmillan director, officer: President and CEO 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Christiana Stamoulis director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST, CAMBRIDGE MA 02139
Scott T Garrett director 35 CROSBY DRIVE, BEDFORD MA 01730
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Sally Crawford director C/O HOLOGIC, INC., BEDFORD MA 01730
Nanaz Mohtashami director 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jennifer M Schneiders officer: President, Diag. Solutions 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Stacey D. Stewart director 5920 WALHONDING ROAD, BETHESDA MD 20816
Elisabeth A Hellmann officer: SVP, Human Resources 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kevin R Thornal officer: Div. President, Diagnostics 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
John M. Griffin officer: General Counsel 250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Erik S Anderson officer: Div. Pres., Breast & Skeletal 250 CAMPUS DRIVE, MARLBOROUGH MA 01752